DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19

开发治疗 COVID-19 的化合物

• 批准号: 10933185
• 负责人: STANLEY WANG
• 金额: $ 846.95万
• 依托单位: ALIGOS THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-22 至 2026-02-15
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10933185
• 关键词: Advanced Development; COVID-19 therapeutics; COVID-19 treatment; Chemistry; Clinical; Development; Pathway interactions; Viral; efficacy evaluation; manufacture; pandemic potential; pathogen; pre-clinical; product development; research and development; safety assessment; therapeutic candidate

To support the advanced development of a promising antiviral against a pathogen with pandemic potential. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

支持针对具有大流行潜力的病原体的有前途的抗病毒药物的高级开发。支持的研发活动将使候选治疗产品通过产品开发途径取得进展，包括临床前和IND使能开发活动、化学优化/开发、GMP生产以及临床安全性和有效性评估。